Oxford Cannabinoid Technologies Holdings Plc

DB:0CB Stock Report

Market Cap: €1.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oxford Cannabinoid Technologies Holdings Valuation

Is 0CB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0CB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0CB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0CB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0CB?

Key metric: As 0CB is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0CB. This is calculated by dividing 0CB's market cap by their current book value.
What is 0CB's PB Ratio?
PB Ratio0.6x
BookUK£1.95m
Market CapUK£1.25m

Price to Book Ratio vs Peers

How does 0CB's PB Ratio compare to its peers?

The above table shows the PB ratio for 0CB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.1x
B8FK Biofrontera
0.9xn/a€15.8m
SBX SynBiotic
1.8x107.0%€27.9m
HIGH Cantourage Group
1.3x112.7%€57.9m
0RX Redx Pharma
16.6x-22.3%€65.0m
0CB Oxford Cannabinoid Technologies Holdings
0.6xn/a€1.3m

Price-To-Book vs Peers: 0CB is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (5.3x).

Price to Book Ratio vs Industry

How does 0CB's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

11 CompaniesPrice / BookEstimated GrowthMarket Cap
0CB 0.6xIndustry Avg. 2.3xNo. of Companies17PB0246810+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0CB is good value based on its Price-To-Book Ratio (0.6x) compared to the European Pharmaceuticals industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is 0CB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0CB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0CB's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

7D

2.0%

1Y

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

7D

5.0%

1Y

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

1.8%

1Y

-31.2%